Literature DB >> 86835

Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

A Szczeklik, R Nizankowski, S Skawinski, J Szczeklik, P Gluszko, R J Gryglewski.   

Abstract

Five patients with advanced arteriosclerosis obliterans of the lower extremities, as evidenced by resting pain, ischaemic ulcers, and focal necrosis, received intra-arterial infusions of prostacyclin at doses of 5--10 ng/kg/min for 72 h. Within 2 days of termination of the infusion, pain at rest had disappeared in all patients. In three of the five, the necrosis had completely regressed and the ischaemic ulcers healed within 2 months. The other two patients showed considerable improvement. Prostacyclin therapy was not associated with changes in the radiographic appearance of the major blood-vessels. However, muscle blood-flow, as measured by xenon-133 clearance, was significantly increased both during prostacyclin infusion and for the 6 weeks of measurement after its termination.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86835     DOI: 10.1016/s0140-6736(79)91792-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2. 

Authors:  C Diehm; H Heidrich; F Spengel; K L Schulte; W Theiss
Journal:  Internist (Berl)       Date:  2000-11       Impact factor: 0.743

3.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

4.  Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.

Authors:  I Virgolini; P Fitscha; H Sinzinger; H Barth
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

6.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

7.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

8.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

9.  Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

Authors:  H Sinzinger; J O'Grady; P Fitscha
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

Review 10.  Prostaglandin I2 (prostacyclin).

Authors:  J G Kelton; M A Blajchman
Journal:  Can Med Assoc J       Date:  1980-01-26       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.